Expertise in
32
conditions

Dr. Amanda Cashen

Oncology
Washington University
4500 Forest Park Ave, 
Saint Louis, MO 
23 Years of Experience
Expertise in
32
conditions
Washington University
4500 Forest Park Ave, 
Saint Louis, MO 

Overview

Amanda Cashen is an Oncologist in Saint Louis, Missouri. Dr. Cashen has been practicing medicine for over 23 years is highly rated in 32 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy.

Her clinical research consists of co-authoring 148 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes Jewish Hospital
Memorial Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Washington University
4500 Forest Park Ave, Saint Louis, MO 63108
Other Locations
Washington University
660 S Euclid Ave, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Procedure
Study Drugs: Anti-thymocyte globulin, Solumedrol, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Drug, Procedure
Study Drug: Duvelisib
Study Phase: Phase 2
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2025
Intervention Type: Procedure, Drug
Study Drugs: Tacrolimus, Mycophenolate mofetil, G-CSF, ALT-803
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drug: CIML NK Cell Infusion
Study Phase: Phase 1/Phase 2
A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
A Pilot Study of Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug, Procedure
Study Drugs: Bendamustine, Rituximab, Acalabrutinib, Cytarabine
Study Phase: Phase 2
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other, Procedure
Study Drug: Itacitinib
Study Phase: Phase 1
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2025
Intervention Type: Procedure
A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma
A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Procedure
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, ALT-803, Cytokine-Induced Natural Killer T Cells, IL-2
Study Phase: Phase 1/Phase 2
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: November 01, 2023
Intervention Type: Drug, Procedure
Study Drugs: Bendamustine, Rituximab, Cytarabine, Pegfilgrastim, Filgrastim
Study Phase: Phase 1
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: August 14, 2023
Intervention Type: Procedure, Drug, Biological
Study Drugs: Personalized tumor vaccine, Poly ICLC, Nivolumab, Rituximab
Study Phase: Phase 1
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: ApoGraft
Study Phase: Phase 1
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 1
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
Enrollment Status: Withdrawn
Publish Date: April 04, 2023
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cytokine induced memory-like NK cells, Fludarabine, Ara-C, G-CSF, Interleukin-2
Study Phase: Phase 2
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Enrollment Status: Withdrawn
Publish Date: March 11, 2022
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Lenalidomide
Study Phase: Phase 1
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas
A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas
Enrollment Status: Completed
Publish Date: November 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 20, 2020
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: November 26, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 16, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 08, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
Enrollment Status: Terminated
Publish Date: October 12, 2018
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 26 Less Clinical Trials

148 Total Publications

Developing a genetic return of results service core.
Developing a genetic return of results service core.
Journal: Journal of clinical and translational science
Published: May 20, 2025
Similar Doctors
Expertise in
34
conditions
Dr. Nancy Bartlett
Oncology
Expertise in
34
conditions
Dr. Nancy Bartlett
Oncology

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Nancy Bartlett is an Oncologist in Saint Louis, Missouri. Dr. Bartlett is highly rated in 34 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
16
conditions
Dr. Ramaswamy Govindan
Oncology
Expertise in
16
conditions
Dr. Ramaswamy Govindan
Oncology

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7578
Languages Spoken:
English
See accepted insurances

Ramaswamy Govindan is an Oncologist in Saint Louis, Missouri. Dr. Govindan is highly rated in 16 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Expertise in
27
conditions
Dr. Angela Hirbe
Oncology
Expertise in
27
conditions
Dr. Angela Hirbe
Oncology

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.2 miles away)
314-362-7216
Languages Spoken:
English
See accepted insurances

Angela Hirbe is an Oncologist in Saint Louis, Missouri. Dr. Hirbe is highly rated in 27 conditions, according to our data. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Neurofibromatosis Type 1 (NF1), and Adult Soft Tissue Sarcoma.

Frequently Asked Questions about Dr. Amanda Cashen

How do I make an appointment with Dr. Amanda Cashen?

You can book an appointment with Dr. Amanda Cashen by calling their office at 314-454-8304. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amanda Cashen a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amanda Cashen is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amanda Cashen specialize in?

While Dr. Amanda Cashen is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Amanda Cashen participate in research or clinical trials?

Yes. Dr. Amanda Cashen has published 148 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Amanda Cashen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amanda Cashen accept my insurance?

Dr. Amanda Cashen accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-454-8304 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cashen's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 14 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile